royalties

As part of the deal with an institutional investor, Interpace's royalty and milestone obligations will also be terminated. 

Life Technologies last week reported a 1 percent decrease in revenues for its Genetic Analysis unit and flat sales in its Applied Sciences unit in the third quarter, contributing to a 2 percent decline in overall company revenues year over year.

By Ben Butkus
Roche has initiated an arbitration hearing against Cepheid in response to Cepheid's decision to terminate its real-time PCR license with Roche, PCR Insider has learned.

Amid reporting its earnings for the third quarter of 2011, Cepheid said today that it is terminating its PCR license with Roche after determining that patents covered by the license are "not pertinent" to Cepheid's future business plans.

The company reported a 3 percent decrease in organic revenue for its Molecular Biology Systems division in the first quarter of 2011 due primarily to "difficult" year-over year comparisons for its PCR and molecular biology reagents businesses.

An institutional investor has suggested that the firm spin out or distribute a royalty asset tied to a Merck phase III drug.

A new licensing team at Life Technologies helped reduce the decline in 2009 PCR patent royalties to around $20 million instead of $30 million, and it appears that 2010 will see no deterioration at all.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.